PROSTATE CANCER METASTATIC
Clinical trials for PROSTATE CANCER METASTATIC explained in plain language.
Never miss a new study
Get alerted when new PROSTATE CANCER METASTATIC trials appear
Sign up with your email to follow new studies for PROSTATE CANCER METASTATIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cocktail of drugs tested for tough prostate cancer
Disease control CompletedThis early-phase study tested a combination of four drugs (apalutamide, abiraterone, docetaxel, and prednisone) in 16 men with metastatic castrate-resistant prostate cancer that had stopped responding to hormone therapy. The main goal was to find a safe dose of apalutamide when g…
Matched conditions: PROSTATE CANCER METASTATIC
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated May 26, 2026 03:19 UTC
-
New drug combo shows promise for Tough-to-Treat prostate cancer
Disease control CompletedThis study tested a combination of two drugs, talazoparib and temozolomide, in 16 men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The goal was to find the safest dose and see if the treatment could shrink tumors. The study was complete…
Matched conditions: PROSTATE CANCER METASTATIC
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:09 UTC
-
New hope for Drug-Resistant prostate cancer? early trial tests combo therapy
Disease control CompletedThis early-stage trial tested a new drug (ARV-110) combined with a standard hormone therapy (abiraterone) in 45 men whose metastatic prostate cancer had stopped responding to abiraterone alone. The main goals were to check safety, find the right dose, and see how the drugs behave…
Matched conditions: PROSTATE CANCER METASTATIC
Phase: PHASE1 • Sponsor: Arvinas Androgen Receptor, Inc. • Aim: Disease control
Last updated May 26, 2026 03:05 UTC